-
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
•
EOC Pharma, a biotech company operating in the US and China, has announced that its New Drug Application (NDA) filing for entinostat has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
-
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
•
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds, raising a total of USD 107 million. The financing was led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital, with participation from Yuexiu Fund and Yuthai Fund. The proceeds will…
-
Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration
•
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced a three-year strategic collaboration aimed at advancing scientific research and development in neuroscience and specialized immunology. This academic partnership marks Biogen’s first collaboration in China, highlighting the company’s commitment to expanding its research footprint in…
-
China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan
•
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have released the “Integrated Pain Management Pilot Work Plan,” aimed at enhancing pain management capabilities in hospitals across China. The plan outlines a pilot program to be implemented from 2022 to 2025, focusing on exploring and…
-
Zhongchao Partners with Natco Pharma to Distribute Drugs in China
•
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with India-headquartered Natco Pharma Limited to become its distribution agent for certain drugs in mainland China. The collaboration aims to address domestic demand for influenza drugs, cancer therapies, and rare disease treatments. The two companies will…
-
By-Health to Establish Nutrition Research Center with Shanghai Institute
•
China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and translation center” in collaboration with the Shanghai Institute of Nutrition and Health (SINH), CAS. This initiative marks a comprehensive upgrade to their existing strategic partnership. Financial details of the collaboration were not disclosed. Background and…
-
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
•
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to secure exclusive global rights to a novel, second – generation gene therapy for spinal muscular atrophy (SMA) from UMass Chan Medical School in the United States. The deal includes all development, manufacturing, and commercialization rights…
-
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
•
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received clinical trial approval in China for TST003, its potential first – in – class monoclonal antibody (mAb) targeting Gremlin1. The drug candidate has already received IND clearance from the US FDA in September this year,…
